Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peginterferon alfacon-1 + ribavirin
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Small Molecules
- Administration
- Subcutaneous (peginterferon Alfacon-1), Oral (ribavirin)
01
Overview
Peginterferon alfacon-1 + ribavirin is a **combination therapy** used primarily for treating chronic hepatitis C virus (HCV) infection, especially in patients who have failed previous interferon-based therapies. Peginterferon alfacon-1 is a recombinant, pegylated type-I interferon (consensus interferon), engineered for increased bioavailability compared to standard interferon, and modulates the immune system through antiviral, antiproliferative, and immunomodulatory mechanisms. Ribavirin is a nucleoside analog with broad-spectrum antiviral activity, acting as a mutagen and immunomodulator. Together, they induce increased sustained virologic response rates compared to monotherapy or non-pegylated interferon combinations. This regimen is typically reserved for retreatment in patients resistant to first-line pegylated interferon plus ribavirin therapy[2][5][6].
- Brand names
- Infergen (peginterferon alfacon-1)Ribasphere (ribavirin)Rebetol (ribavirin)
- Other names
- consensus interferon + ribavirinCIFN + ribavirin
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)RdRp (Coronavirus RNA-dependent RNA polymerase)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)
Beyond the preview
Go deeper on peginterferon alfacon-1 + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peginterferon alfacon-1 + ribavirin.